Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Myeloproliferative neoplasms-unclassifiable (MPN-U): A carefully curated series of 30 Mayo Clinic patients

View Full Paper
Ask AI
Bookmark
Share

Authors

RARania AbdelazizMayo ClinicSFSaubia FathimaMayo ClinicKRKaaren K. ReichardMayo Clinic

Discussion

Loading...

Member takes

Overview

Cohort study reports venous thrombosis and diagnostic challenges in myeloproliferative neoplasm-unclassifiable, indicating similarities to essential thrombocythemia.

Key Points

  • To define the presentation and outcomes of patients with myeloproliferative neoplasm-unclassifiable compared to essential thrombocythemia.
  • Cohort study including 30 patients with MPN-U and 658 with ET
  • Utilized the ICC diagnostic criteria
  • Screened for mutations using next-generation sequencing
  • Conducted statistical analysis with JMP Pro 18.0.0
  • MPN-U showed higher prevalence of JAK2 mutations (87%) and lower CALR mutations (3%) compared to ET
  • Patients with MPN-U were more likely to present with venous thrombosis (43%)
  • Long-term survival rates were similar between MPN-U and ET (15-year survival 70% vs. 65%)

Cite This Study

Abdelaziz et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4f8https://doi.org/10.1182/blood-2025-7314
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Single Center’s Experience in the Diagnosis and Treatment of Myeloproliferative Neoplasms2025
  2. 2Epidemiology and outcomes of patients with myeloproliferative neoplasms in the United States: A SEER database analysis, years 2000-20212025
  3. 3Thrombotic Events and Overall Survival in BCR-ABL1 Negative Myeloproliferative Neoplasms: A Single-Center Analysis2026
  4. 4Myelodysplastic/myeloproliferative overlap neoplasms: Clinicopathological features, treatment strategies, and outcomes — a UK multicentre cohort Study2025
  5. 5Clinical features and outcomes of myeloproliferative neoplasm patients with MPL mutations and concurrent JAK2/calr mutations2025